SGHTNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Sight Sciences, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$8.26−0.02 (-0.24%)
Close on Oct 19, 2026
- Market cap
- $450.22M
- P/E (TTM)
- –
- Dividend yield
- –
Sight Sciences, Inc. revenue by segment
By business segment
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Interventional Glaucoma | $20.71M | $18.34M | $19.66M | $19.72M | $19.23M | $17.11M | $18.77M | $18.63M | $20.24M | $18.26M | $17.15M | $18.43M | 88.6% | +7.7% |
| Interventional Dry Eye | $2.68M | $1.35M | $724.00K | $188.00K | $333.00K | $394.00K | $304.00K | $1.53M | $1.13M | $1.01M | $1.60M | $1.58M | 11.4% | +703.3% |
By product or service
By region
From the segment and revenue-disaggregation notes of Sight Sciences's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.